Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose valsartan crossover study for sympathetic hyperactivity in chronic kidney disease and hypertension
NL-OMON31295Phase 3Withdrawn
- Sponsor
- University Medical Center Utrecht
- Start
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of valsartan in hypertension (HTN) and chronic kidney disease (CKD) (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Effect of increasing valsartan dose on muscle sympathetic nerve activity. Planned start Oct 2007; status: withdrawn.
02
Drugs
valsartan
03
Conditions
hypertension (HTN)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NL-OMON31295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31295.